Vyome Delivers Breakthrough 2025 Performance, Sets Stage for Next Growth Chapter

Vyome is building the world’s premier platform spanning the US-India innovation corridor. With a focus on immuno-inflammatory conditions, Vyome is committed to delivering breakthrough therapies in a cost-efficient manner while upholding global standards of quality and safety.

Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND), a next-generation inflammation-focused biotech leveraging the US-India innovation corridor, today announced its transformational 2025 results, marking its first annual reporting period as a Nasdaq-listed company.

Vyome has emerged as a disciplined, innovation-driven clinical-stage company, well-positioned to accelerate development across immuno-inflammatory and orphan indications.

Krishna Gupta, Chairman of Vyome, stated:“Vyome is targeting one of the biggest challenges in the world today – inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure or the development of our assets.”

Venkat Nelabhotla, CEO of Vyome, added:“This annual reporting marks a defining step forward. The promising final Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With disciplined operations, clean capital structure, and a world-class team, we are well-positioned to deliver milestones ahead and drive long-term value for both shareholders and patients.”

VT-1953: Breakthrough in Malignant Fungating Wounds (MFW)

Final Phase 2 study demonstrated statistically significant reduction in malodor (P<0.002), alongside pain reduction and improved quality of life.
VT-1953 continues to show an excellent safety profile.
Destum Partners valued VT-1953 at approximately $1 billion post pivotal study success.
FDA Orphan Drug Designation application submitted in January 2026; pivotal study design discussions expected in Q2 2026.
MFW, a devastating rare condition affecting 5–14% of advanced cancer patients, represents a $2.2B U.S. market opportunity with no FDA-approved therapies.

Financial & Operational Highlights

Cash position of $4.94M as of December 31, 2025, bolstered by $5.3M financing in January 2026.
Cash runway expected to extend through mid-2027, covering pivotal trial interim readouts.
Net loss of $10.47M primarily reflects one-time merger and financing-related expenses.
Clean capital structure: 5.9M outstanding shares of common stock, no preferred stock, no debt.

Strengthened Leadership Team

Vyome added a new Chief Technology Officer, Senior VP of Clinical Development, and Senior Medical Advisor – all with Big Pharma backgrounds and proven track records across multiple FDA-approved therapies.